Sitagliptin Preserves Hip Bone Density in Women with Type 2 Diabetes: SLowDOWN Trial
A 52-week phase III RCT finds sitagliptin preserves hip bone density in women with type 2 diabetes, which declines on placebo, but with no effect at other sites. PICO summary and commentary.
